| Filed On | Filing |
|---|---|
| 27 Oct 2026 | SCHEDULE 13G |
| 19 Oct 2026 |
8-K: Results of Operations and Financial Condition; Cost Associated with Exit or Disposal Activities +1 more
WATERTOWN, Mass., October 19, 2026 (GLOBE NEWSWIRE) – EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today anno... |
| 19 Oct 2026 |
8-K: Other Events
– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement – |
| 07 Oct 2026 | SCHEDULE 13G/A |
| 10 Sep 2026 |
8-K: Other Events
LUGANO Phase 3 Clinical Trial DURAVYU in Wet AMD Expanded Results & Analyses | September 2026 Exhibit 99.1 |
| 08 Sep 2026 | SCHEDULE 13G |
| 24 Aug 2026 |
Form 4: Elston George, Chief Financial Officer
Disposed of 5,000 shares (Other Transaction) · Acquired 5,000 shares (Other Transaction) · Gave 64,953 shares as a gift · 1 more |
| 18 Aug 2026 |
Form 4: Zaderej Karen L., Director
Bought 10,600 shares ($52.3K) |
| 17 Aug 2026 | 8-K: Other Events |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 | S-8 |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 31 Jul 2026 | SCHEDULE 13G |
| 30 Jul 2026 | 8-K: Other Events |
| 28 Jul 2026 | SCHEDULE 13G/A |
| 22 Jul 2026 | 144/A |
| 22 Jul 2026 | 144/A |
| 21 Jul 2026 | 144 |
Loading...
